The 2014 All-Japan Research Team: Health Care & Pharmaceuticals, No. 3: Atsushi Seki
Institutional Investor Research is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

The 2014 All-Japan Research Team: Health Care & Pharmaceuticals, No. 3: Atsushi Seki

< The 2014 All-Japan Research Team Atsushi Seki Barclays First-place appearances: 0


Total appearances: 2


Analyst debut: 2013 Barclays’s Atsushi Seki debuted as a runner-up in 2013 and takes a step up to third place this year. Investors praise him for providing useful daily updates — and his “report on pharmaceuticals price revision,” one advocate reports, was especially beneficial. Seki predicts that “the sector’s focus will be on innovation and cost reduction” this year, supported by “good news flow from oncology research and development.” Two names that currently earn his favor are Tokyo-headquartered drugmakers Chugai Pharmaceutical Co. and Otsuka Holdings Co. He believes that Chugai will continue to benefit from its long-standing partnership with Switzerland’s Roche Holdings, its majority shareholder, and from its internal research and development for lung cancer and hemophilia treatments. His target price for the shares is ¥2,600, representing an 8.2 percent upside to their mid-March value. Otsuka’s stock, the researcher advises, is oversold ahead of the April 2015 expiration of its patent on Abilify, a drug used to treat bipolar disorder, depression and schizophrenia. But the company “will be able to grow after patent expiry,” he forecasts, “with Abilify follow-on compounds and other assets.” At ¥2,963 in mid-March, the share price could reasonably rise as high as ¥4,000, Seki contends.



Gift this article